MorphoSys expanded the clinical development of guselkumab into ulcerative colitis, a chronic inflammatory disease of the large intestine. Janssen initiated a proof-of-concept phase 2a clinical trial in patients with moderately to severely active ulcerative colitis UC. The randomized, double-blind study will evaluate the efficacy and safety of guselkumab in combination with golimumab compared to gusel kumab or golimumab monotherapy in 210 patients with moderately to severely active UC.